Epilepsy and Medical Cannabis: Research Overview

Understanding Epilepsy and Seizure Research

Epilepsy is a neurological condition characterized by recurrent seizures, which are sudden disruptions in normal brain activity. Because seizure management is complex, researchers constantly investigate new pathways for treatment. The summaries below are based on several studies found in PubMed, the U.S. National Library of Medicine’s database of peer-reviewed research. This overview is for educational purposes and is not medical advice; always consult a licensed physician for clinical guidance.

The Landscape of CBD and Cannabinoid Use

A review in JAMA examines how widely cannabinoids are used in North America. The study notes that nearly 27% of adults in the U.S. and Canada have used cannabis for medical purposes, while about 10.5% of the U.S. population uses cannabidiol (CBD)—a non-psychoactive compound extracted from cannabis.

The same journal outlines which conditions currently hold FDA approval for cannabinoid use, including certain pediatric seizure disorders, alongside nausea related to chemotherapy and HIV/AIDS-related anorexia.

CBD in Severe, Drug-Resistant Epilepsy

Some epilepsy types are exceptionally difficult to treat. A systematic review in CNS drugs focused on developmental and epileptic encephalopathies (DEEs). These are severe, drug-resistant forms of epilepsy that often cause significant developmental and behavioral issues. While pharmaceutical-grade CBD has shown some efficacy in Dravet syndrome and Lennox-Gastaut syndrome, the researchers noted that evidence across the wider DEE spectrum remains fragmented.

Another review in CNS & neurological disorders drug targets highlighted the challenge that roughly one-third of patients with epilepsy are resistant to standard treatments. The study explored how CBD may offer potential by simultaneously addressing seizure control and motor abnormalities often seen in these patients.

Safety and Cellular Mechanisms

Research also looks at what happens at the cellular level. A study in Archives of toxicology examined the drug Epidiolex, which received FDA approval for certain childhood-onset seizures. The researchers identified liver toxicity as a significant side effect and observed cytotoxicity in HepG2 cells caused by CBD and its metabolites, including disturbances to the cell cycle and endoplasmic reticulum stress.

Sodium Channels and Cognitive Impact

Beyond CBD, research investigates the underlying physiology of nerves. A review in Neural regeneration research analyzed voltage-gated sodium channels (including Nav1.1, Nav1.2, and Nav1.6) and their essential role in modulating neuronal excitability and signal transmission.

Additionally, a review in Epilepsia looked at interictal epileptiform discharges (IEDs)—spikes that occur between seizures. These are not just markers but are associated with cognitive and behavioral dysfunction. The review examined how antiseizure medications can modulate these IEDs, which may have implications for improving cognition and behavior.

A Developing Field of Study

The science surrounding epilepsy and cannabinoid use is still evolving. These findings are based on the abstracts of the studies listed above and should not be used to make decisions about your health. If you have questions about seizure management or CBD, please schedule a consultation with your licensed physician.